Muscle Spasticity Clinical Trial
Official title:
Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy
Cerebral palsy (CP) is the most common neuromuscular disorder among children, resulting from
a non-progressive injury during early brain development which leads to impairment of
movement and posture.
Muscle weakness and spasticity associated with CP limit the joint range of motion and
negatively impact ambulatory ability. Most ambulatory children with CP are prescribed with
ankle-foot orthoses (AFOs) to improve ankle position and stability and to maintain muscle
range. Nevertheless, AFOs may also restrict desired motions and may exacerbate muscle
weakness and atrophy.
During the last years a novel method is being used for treating upper motor neuron drop
foot, by means of dynamic orthoses, namely Functional Electrical Stimulation (FES).
These FES devices cause dorsiflexion of foot by stimulating the peroneal nerve and
activating the tibialis anterior muscle. Most of the studies of FES devices were conducted
on adult population. These studies showed improvement in laboratory and functional gait
parameters. There are relatively few studies on children with hemiplegic or diplegic CP with
favorable results. There is no solid evidence whether the improvements seen in laboratory
setting of children with CP, are reflected on functional ambulation in daily life. In
addition, there are no defined parameters which could predict the response to FES among
those children.
The aim of this study is to determine whether using FES device (WalkAide; Innovative
Neurotronics, Austin, TX, USA) improves daily motor function and gait parameters in children
with spastic hemiplegic or diplegic CP. additionally, we aim to define clinical and
biomechanical parameters that can predict a favorable response to using the FES device.
Cerebral palsy (CP) is the most common neuromuscular disorder among children, resulting from
a non-progressive injury during early brain development which leads to impairment of
movement and posture.
Individuals with CP exhibit a wide range of motor disabilities; however, approximately 70%
of them achieve the ability to ambulate during childhood, albeit with difficulty.
Muscle weakness and spasticity associated with CP limit the joint range of motion and
negatively impact ambulatory ability. The ankle joint is affected in virtually all patients.
Insufficient ankle dorsiflexion during swing, foot drop and excessive plantar flexion during
early to mid-stance may cause standing and walking instability with greater risk for
falling. Most ambulatory children with CP are prescribed with ankle-foot orthoses (AFOs) to
improve ankle position and stability for standing and walking and to maintain muscle range.
Nevertheless, AFOs may also restrict desired motions and may exacerbate muscle weakness and
atrophy, leading to further loss of function over time. In addition many children,
especially adolescents, avoid using AFOs because of discomfort and concerns regarding
negative effects on body image.
During the last years a novel method is being used for treating upper motor neuron drop
foot, by means of dynamic orthoses, namely Functional Electrical Stimulation (FES).
These FES devices cause dorsiflexion of foot by stimulating the peroneal nerve and
activating the tibialis anterior muscle.
FES devices, by actively stimulating the muscle have theoretical advantages over static
AFOs. In addition the stimulator can be cosmetically better accepted.
Most of the studies of FES devices were conducted on adult population with upper motor
neuron defect. These studies showed improvement in laboratory and functional gait
parameters.In addition to the direct orthotic effect of the device during utilization, some
studies also indicated a therapeutic effect ("carry over effect"), which was postulated to
arise through the neural plasticity facilitation by increasing the strength of afferent
feedback inputs to CNS. Whether this therapeutic effect actually exists and for how long is
still unclear.
A variety of Functional Electrical Stimulation (FES) devices are being increasingly
prescribed as a treatment option in CP children. There are relatively few studies on
children with hemiplegic or diplegic CP. Prosser et al(Prosser et al 2013), reported good
acceptability of FES device in CP population. Other studies have showed as well favorable
results, with improvement of ankle kinematics parameters, such as dorsiflexion angle at
swing phase and initial contact. Damiano et al (Damiano et al 2012) showed evidence of
use-dependent muscle plasticity with increased tibialis anterior muscle thickness while
using FES devices in CP patients.
There is still no solid evidence whether the improvements seen in laboratory setting are
reflected on functional ambulation in daily life. Some studies showed improvement in walking
speed while others did not.
Moreover, some studies also indicated an effect variability among subjects, which could be
partially explained by the heterogeneity of CP population. There are no defined parameters
which could predict the response to FES among those children.
The WalkAide(WalkAide; Innovative Neurotronics, Austin, TX, USA) is a battery-operated,
small medical electrical stimulator device, which attaches to a molded cuff located just
below the knee and produces controlled dorsiflexion of the foot during walk.It utilizes a
tilt sensor and accelerometer to control the timing and duration of the stimulation during
walking.Use of the Tilt Sensor to trigger stimulation eliminates the need for additional
components or external wires.
The aim of this study is to determine whether using WalkAide device, improves daily motor
function and gait parameters in children with spastic hemiplegic or diplegic CP. In
addition, we aim to define clinical and biomechanical parameters that can predict a
favorable response to using the FES device.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT02907775 -
Multi-channel Stimulation for Post Stroke Spasticity (MUSTS)
|
N/A | |
Recruiting |
NCT04530955 -
Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)
|
N/A | |
Active, not recruiting |
NCT03521076 -
Randomized Controlled Trial of Virtual Reality
|
N/A | |
Completed |
NCT03080454 -
The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
|
Phase 1/Phase 2 | |
Completed |
NCT02546999 -
Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?
|
Phase 4 | |
Active, not recruiting |
NCT01041157 -
Botulinum Toxin Injection Efficiency
|
Phase 1 | |
Terminated |
NCT00531466 -
Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury
|
Phase 2 | |
Terminated |
NCT00532532 -
Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT00535938 -
MDs on Botox Utility (MOBILITY)
|
N/A | |
Completed |
NCT05546190 -
A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)
|
||
Recruiting |
NCT06117020 -
Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
|
Phase 1 | |
Completed |
NCT01603628 -
BOTOX® Treatment in Pediatric Lower Limb Spasticity
|
Phase 3 | |
Completed |
NCT05510726 -
Quantitative Evaluation of Muscle Stiffness in Neurological Patients With Muscle Overactivity
|
||
Not yet recruiting |
NCT04378946 -
Error Augmentation Motor Learning Training Approach in Stroke Patients
|
N/A | |
Completed |
NCT01603615 -
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
|
Phase 3 | |
Completed |
NCT01251380 -
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
|
Phase 3 | |
Completed |
NCT00549783 -
BOTOX® Economic Spasticity Trial (BEST)
|
Phase 4 | |
Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
Completed |
NCT00076687 -
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
|
Phase 2 |